Search research articles
Contact Us
Filters
Showing results (31-40 of 177) with videos related to
Page
of 18
Sort By:
American Journal of Hematology
|
April 25, 2025
Elotuzumab in Combination With Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients With Relapsed/Refractory Plasma Cell Dyscrasia and Advanced Organ Involvement
Tobias Dittrich, Timon Hansen, Christoph R Kimmich, et al.
Hematological Oncology
|
March 19, 2015
Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function
Iris Breitkreutz, Natalia Becker, Axel Benner, et al.
Haematologica
|
November 4, 2006
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure
Marc S Raab, Iris Breitkreutz, Michael Hundemer, et al.
Cancer
|
April 28, 2011
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone
Ulrike Klein, Anna Jauch, Thomas Hielscher, et al.
British Journal of Haematology
|
August 8, 2019
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
Roman Hájek, Michel Delforge, Marc S Raab, et al.
British Journal of Haematology
|
September 15, 2007
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma
Iris Breitkreutz, Marc S Raab, Sonia Vallet, et al.
Bone Marrow Transplantation
|
May 13, 2026
Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma
Leo Rasche, Maria Theresa Krauth, Hermine Agis, et al.
Transplantation and Cellular Therapy
|
June 22, 2023
Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation
Lukas John, Sandra Sauer, Ute Hegenbart, et al.
Journal of Cell Science
|
February 22, 2012
STIL is required for centriole duplication in human cells
Julia Vulprecht, Ahuvit David, Alexandra Tibelius, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
October 18, 2021
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view
Ivana von Metzler, Julia Campe, Sabine Huenecke, et al.
Page
of 18
Search research articles
Search
Showing results (31-40 of 177) with videos related to
Sort By:
Page
of 18
American Journal of Hematology
|
April 25, 2025
Elotuzumab in Combination With Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients With Relapsed/Refractory Plasma Cell Dyscrasia and Advanced Organ Involvement
Tobias Dittrich, Timon Hansen, Christoph R Kimmich, et al.
Hematological Oncology
|
March 19, 2015
Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function
Iris Breitkreutz, Natalia Becker, Axel Benner, et al.
Haematologica
|
November 4, 2006
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure
Marc S Raab, Iris Breitkreutz, Michael Hundemer, et al.
Cancer
|
April 28, 2011
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone
Ulrike Klein, Anna Jauch, Thomas Hielscher, et al.
British Journal of Haematology
|
August 8, 2019
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
Roman Hájek, Michel Delforge, Marc S Raab, et al.
British Journal of Haematology
|
September 15, 2007
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma
Iris Breitkreutz, Marc S Raab, Sonia Vallet, et al.
Bone Marrow Transplantation
|
May 13, 2026
Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma
Leo Rasche, Maria Theresa Krauth, Hermine Agis, et al.
Transplantation and Cellular Therapy
|
June 22, 2023
Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation
Lukas John, Sandra Sauer, Ute Hegenbart, et al.
Journal of Cell Science
|
February 22, 2012
STIL is required for centriole duplication in human cells
Julia Vulprecht, Ahuvit David, Alexandra Tibelius, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
October 18, 2021
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view
Ivana von Metzler, Julia Campe, Sabine Huenecke, et al.
Page
of 18